Sesen Bio Inc investor relations material
Listen to the latest call from Sesen Bio Inc
Sesen Bio is developing fusion protein therapeutics for the treatment of patients with cancer based on a proprietary platform technology. This technology utilizes proprietary ligand design, a data-driven computational approach to molecular modeling, and molecular engineering to develop a library of novel fusion protein therapeutics. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Ticker
SESNCountry
USAbout
IR-page